Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China

A split-virion trivalent inactivated influenza vaccine produced according to the Chinese pharmacopeia (Shz-IIV3) has been commercially available in China since 2014. Here, we describe the results of a phase IV open-label trial to describe the immunogenicity and safety of the 2014–2015 Northern Hemis...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Zhaojun, Nong, Yi, Liu, Shuzhen, Shao, Ming, Liao, Xueyan, Go, Kerry, Lavis, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489275/
https://www.ncbi.nlm.nih.gov/pubmed/28301266
http://dx.doi.org/10.1080/21645515.2017.1285475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489275/
https://www.ncbi.nlm.nih.gov/pubmed/28301266
http://dx.doi.org/10.1080/21645515.2017.1285475

Ejemplares similares